Supplement firms face injunction for health claims
This article was originally published in The Tan Sheet
FDA announces a permanent injunction against Brownwood Acres Foods and Cherry Capital Services, and two of their executives as a result of unapproved drug claims and unauthorized health claims about their products, which include liquid glucosamine and salmon oil capsules, agency reports Feb. 22. According to FDA, the firms and executives agreed to a consent decree that prohibits them from manufacturing and distributing products claimed to "cure, treat, mitigate or prevent diseases." Signed by a U.S. District Court in Michigan, the decree requires the firms to remove the claims from the labels of products, Web sites and brochures, and hire an expert to review claims. FDA notes firms cannot make such claims until products "are approved by the FDA as new drugs, exempt from approval as investigational new drugs, or until the claims on the products' label ... comply with the law"...
You may also be interested in...
The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.